NewLink Genetics weakness creates buying opportunity, says Cantor Cantor reports that NewLink's stock has been pressured since the announcement of the continuation of the IMPRESS trial of its pancreatic cancer drug to the next review point. The firm expected this to occur but notes that the timing of the continuation has raised concerns about survival rates and the possibility that the control arm is performing better than expected. Cantor thinks it's too early to be concerned about these issues, and raised its price target on the shares to $34 from $30 while keeping a Buy rating on the stock.
NewLink Genetics falls after Ebola vaccine trial suspended Shares of NewLink Genetics (NLNK) are falling in pre-market trading after a clinical trial of the Ebola vaccine being developed by the company and partner Merck (MRK) was temporarily suspended as a precautionary measure after four patients complained of joint pains in their hands and feet, the University of Geneva Hospital said. The trials are scheduled to resume next month in up to 15 volunteers after checks to make sure that the joint pain symptoms were benign and temporary, the hospital added. Shares of NewLink are down 6.5% to $34.50 in early morning trading following the news, while Merck shares are indicated to open fractionally higher.